Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models
Overall, a mucosal multivalent live NDV-HXP-S vaccine shows great promise as a safe, next-generation vaccine conferring broad mucosal and systemic immunity against future SARS-CoV-2 variants.
Authors
- Weina Sun (ORCID: https://orcid.org/0000-0002-2435-5047)
- Nicholas Lemus (ORCID: https://orcid.org/0009-0006-9055-6513)
- Peter Palese (ORCID: https://orcid.org/0000-0002-0337-5823)
- Michael Schotsaert (ORCID: https://orcid.org/0000-0003-3156-3132)
- Stephen McCroskery
- Juan Manuel Carreño (ORCID: https://orcid.org/0000-0002-9039-9275)
- Temima Yellin (ORCID: https://orcid.org/0009-0009-1907-0336)
- Stefan Slamanig (ORCID: https://orcid.org/0000-0003-3694-6597)
- Prajakta Warang (ORCID: https://orcid.org/0000-0002-5571-8277)
- Lauren A. Chang (ORCID: https://orcid.org/0000-0002-3287-3987)
- Gagandeep Singh (ORCID: https://orcid.org/0000-0001-5848-2741)
- Anass Abbad (ORCID: https://orcid.org/0000-0002-4617-0473)
- Florian Krammer (ORCID: https://orcid.org/0000-0003-4121-776X)
- Tsoi Ying Lai
- Victoria Dolange (ORCID: https://orcid.org/0000-0001-5410-2342)
- Marina Bárcena‐Varela (ORCID: https://orcid.org/0000-0001-7868-7939)
- José Luis Martínez-Guevara
- Irene González‐Domínguez (ORCID: https://orcid.org/0000-0002-7920-5505)
- Adam Abdeljawad
- Marta Boza (ORCID: https://orcid.org/0009-0003-0015-8676)
Institutions
- Netherlands Institute for Neuroscience (NL)
- Medical University of Vienna (AT)
- University of Amsterdam (NL)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1524477
- Citations
- 8
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 11.17
Funders
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases